Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
REVIEW
Naiela E Almansouri, Mishael Awe, Selvambigay Rajavelu, Kudapa Jahnavi, Rohan Shastry, Ali Hasan, Hadi Hasan, Mohit Lakkimsetti, Reem Khalid AlAbbasi, Brian Criollo Gutiérrez, Ali Haider
Cardiovascular diseases (CVDs) are significant health issues that result in high death rates globally. Early detection of cardiovascular events may lower the occurrence of acute myocardial infarction and reduce death rates in people with CVDs. Traditional data analysis is inadequate for managing multidimensional data related to the risk prediction of CVDs, heart attacks, medical image interpretations, therapeutic decision-making, and disease prognosis due to the complex pathological mechanisms and multiple factors involved...
March 2024: Curēus
#22
JOURNAL ARTICLE
Karen Abboud, Godsfavour Umoru, Barry Trachtenberg, Veronica Ajewole
BACKGROUND: Oral cancer therapy-related cardiovascular (CV) toxicity has a wide variety of presentations including arrhythmia, cardiomyopathy, and myocardial infarction, but clinical evidence related to its management is limited. The purpose of this IRB-approved, single-center, retrospective, cohort study was to characterize cardio-oncologic interventions for CV adverse events related to oral oncolytics. METHODS: The cohort included 67 patients who were admitted to a multi-hospital health system between June 1, 2016 and July 31, 2021, had at least one medical record order of oral oncolytics considered to have cardiotoxic potential, and had an ICD10 code for a cardiotoxic event added to their electronic medical records after initiation of oral oncolytics...
April 9, 2024: Cardio-Oncology
#23
JOURNAL ARTICLE
Tianwei Meng, Zhiping Liu, Jiawen Liu, Xiaobing Zhang, Chengjia Li, Jiarui Li, Boyu Wang, Yinxiong He, Zengguang Fan, Shilong Xin, Jia Chen, Rui Qie
BACKGROUND: Previous observational studies have suggested associations between Coronary Heart Disease (CHD) and Mental Health Disorders (MHD). However, the causal nature of these relationships has remained elusive. OBJECTIVE: The purpose of this study is to elucidate the causal relationships between eight distinct types of CHD and six types of MHD using Mendelian randomization (MR) analysis. METHODS: The MR analysis employed a suite of methods including inverse variance-weighted (IVW), MR-Egger, weighted mode, weighted median, and simple mode techniques...
April 8, 2024: Heart & Lung: the Journal of Critical Care
#24
JOURNAL ARTICLE
Christian Paludan-Müller, Oliver B Vad, Niels K Stampe, Søren Z Diederichsen, Laura Andreasen, Laia M Monfort, Emil L Fosbøl, Lars Køber, Christian Torp-Pedersen, Jesper H Svendsen, Morten S Olesen
BACKGROUND AND AIMS: Patients with atrial fibrillation (AF) are at increased risks of cardiovascular diseases and mortality, but risks according to age at diagnosis have not been reported. This study investigated age-specific risks of outcomes among patients with AF and the background population. METHODS: This nationwide population-based cohort study included patients with AF and controls without outcomes by the application of exposure density matching on the basis of sex, year of birth, and index date...
April 9, 2024: European Heart Journal
#25
JOURNAL ARTICLE
Călin-Dinu Hădăreanu, Diana-Ruxandra Hădăreanu, Flavia-Mihaela Stoiculescu, Victor-Cornel Raicea, Georgică-Costinel Târtea, Cristina Florescu, Răzvan Ilie Radu, Ionuț Donoiu
(1) Introduction and Aims: Right ventricular (RV) remodeling significantly impacts the prognosis of dilated cardiomyopathy (DCM) patients, and right atrial (RA) size and function are still often neglected in DCM patients. Accordingly, our aims were to (i) evaluate right heart subclinical changes and (ii) the prognostic value of RA compared to left atrial (LA) size and function in patients with DCM by advanced echocardiography. (2) Materials and Methods: Sixty-eight patients with DCM (with a mean age of 60 years; 35 men) were evaluated by comprehensive transthoracic echocardiography, compared to 62 age- and sex-matched healthy controls (with a mean age of 61 years; 32 men), and followed up for 12...
February 28, 2024: Journal of Clinical Medicine
#26
JOURNAL ARTICLE
Dominik Linz, Jason G Andrade, Elena Arbelo, Giuseppe Boriani, Guenter Breithardt, A John Camm, Valeria Caso, Jens Cosedis Nielsen, Mirko De Melis, Tom De Potter, Wolfgang Dichtl, Søren Zoega Diederichsen, Dobromir Dobrev, Nicolas Doll, David Duncker, Elke Dworatzek, Lars Eckardt, Christoph Eisert, Larissa Fabritz, Michal Farkowski, David Filgueiras-Rama, Andreas Goette, Eduard Guasch, Guido Hack, Stéphane Hatem, Karl Georg Haeusler, Jeff S Healey, Hein Heidbuechel, Ziad Hijazi, Lucas H Hofmeister, Leif Hove-Madsen, Thomas Huebner, Stefan Kääb, Dipak Kotecha, Katarzyna Malaczynska-Rajpold, José Luis Merino, Andreas Metzner, Lluís Mont, Ghulam Andre Ng, Michael Oeff, Abdul Shokor Parwani, Helmut Puererfellner, Ursula Ravens, Michiel Rienstra, Prashanthan Sanders, Daniel Scherr, Renate Schnabel, Ulrich Schotten, Christian Sohns, Gerhard Steinbeck, Daniel Steven, Tobias Toennis, Stylianos Tzeis, Isabelle C van Gelder, Roderick H van Leerdam, Kevin Vernooy, Manish Wadhwa, Reza Wakili, Stephan Willems, Henning Witt, Stef Zeemering, Paulus Kirchhof
AIMS: Recent trial data demonstrate beneficial effects of active rhythm management in patients with atrial fibrillation (AF) and support the concept that a low arrhythmia burden is associated with a low risk of AF-related complications. The aim of this document is to summarize the key outcomes of the 9th AFNET/EHRA Consensus Conference of the Atrial Fibrillation NETwork (AFNET) and the European Heart Rhythm Association (EHRA). METHODS AND RESULTS: Eighty-three international experts met in Münster for 2 days in September 2023...
March 30, 2024: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
#27
JOURNAL ARTICLE
J J Wedman, O C M Sibon, E Mastantuono, A Iuso
Coenzyme A (CoA) is an essential cofactor required for over a hundred metabolic reactions in the human body. This cofactor is synthesized de novo in our cells from vitamin B5, also known as pantothenic acid, a water-soluble vitamin abundantly present in vegetables and animal-based foods. Neurodegenerative disorders, cancer, and infectious diseases have been linked to defects in de novo CoA biosynthesis or reduced levels of this coenzyme. There is now accumulating evidence that CoA limitation is a critical pathomechanism in cardiac dysfunction too...
April 9, 2024: Journal of Inherited Metabolic Disease
#28
JOURNAL ARTICLE
Yun-Hu Chen, Mo-Qing Yin, Li-Hua Fan, Xue-Chun Jiang, Hong-Feng Xu, Xing-Yu Zhu, Tao Zhang
INTRODUCTION: Malnutrition is strongly associated with heart failure (HF); however, the causal link remains unclear. We used Mendelian randomization (MR) to infer causal associations between different nutritional assessment phenotypes and HF and to analyze whether these associations were mediated by common HF risk factors. METHODS: Two-sample bidirectional MR was used to infer causal associations between nutritional assessment phenotypes and HF. Mutual influences between different nutritional assessment phenotypes and potential correlations were estimated using multivariate MR methods...
April 15, 2024: Heliyon
#29
JOURNAL ARTICLE
Yifei Yang, Xiaoxue Li, Yan Gu, Zhenyu Lyu, Yongmei Liang, Meng Jiao, Mei Jin
BACKGROUND: The prognosis of children with heart failure varies considerably. After treatment, left ventricular ejection fraction (LVEF) can be improved in some children. The aim of this study was to analyze the clinical features of children with heart failure accompanied by cardiomyopathy and recovered ejection fraction [heart failure with recovered ejection fraction (HFrecEF)] and to identify the predictors of improved LVEF. METHODS: Children diagnosed with heart failure in Beijing Anzhen Hospital Affiliated to Capital Medical University from 2018 to 2021 were retrospectively enrolled...
March 27, 2024: Translational Pediatrics
#30
RANDOMIZED CONTROLLED TRIAL
Marcelo Carvalho Vieira, Fernanda de Souza Nogueira Sardinha Mendes, Paula Simplício da Silva, Gilberto Marcelo Sperandio da Silva, Flavia Mazzoli-Rocha, Andrea Silvestre de Sousa, Roberto Magalhães Saraiva, Marcelo Teixeira de Holanda, Daniel Arthur Barata Kasal, Henrique Silveira Costa, Juliana Pereira Borges, Michel Silva Reis, Luiz Fernando Rodrigues Junior, Alejandro Marcel Hasslocher-Moreno, Pedro Emmanuel Alvarenga Americano do Brasil, Mauro Felippe Felix Mediano
To investigate the effect of an exercise-based cardiac rehabilitation program on the quality of life (QoL) of patients with chronic Chagas cardiomyopathy (CCC). PEACH study was a single-center, superiority randomized clinical trial of exercise training versus no exercise (control). The sample comprised Chagas disease patients with CCC, left ventricular ejection fraction < 45%, without or with HF symptoms (CCC stages B2 or C, respectively). QoL was assessed at baseline, after three months, and at the end of six months of follow-up using the SF-36 questionnaire...
April 8, 2024: Scientific Reports
#31
JOURNAL ARTICLE
Keitaro Akita, Shigetaka Kageyama, Sayumi Suzuki, Kazuto Ohno, Masamitsu Kamakura, Ryuzo Nawada, Chiei Takanaka, Yasushi Wakabayashi, Takahiro Kanda, Kei Tawarahara, Masahiro Mutoh, Masaki Matsunaga, Satoru Suwa, Yasuyo Takeuchi, Hiroki Sakamoto, Hideki Saito, Kazusa Hayashi, Nobuyuki Wakahara, Kyoko Unno, Takenori Ikoma, Ryota Sato, Keisuke Iguchi, Terumori Satoh, Makoto Sano, Kenichiro Suwa, Yoshihisa Naruse, Hayato Ohtani, Masao Saotome, Yuichiro Maekawa
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is often concomitant with sleep-disordered breathing (SDB), which can cause adverse cardiovascular events. Although an appropriate approach to SDB prevents cardiac remodelling, detection of concomitant SDB in patients with HCM remains suboptimal. Thus, we aimed to develop a machine learning-based discriminant model for SDB in HCM. METHODS: In the present multicentre study, we consecutively registered patients with HCM and performed nocturnal oximetry...
April 8, 2024: Heart
#32
JOURNAL ARTICLE
Mikhail N Kosiborod, Mark C Petrie, Barry A Borlaug, Javed Butler, Melanie J Davies, G Kees Hovingh, Dalane W Kitzman, Daniél V Møller, Marianne B Treppendahl, Subodh Verma, Thomas J Jensen, Karoline Liisberg, Marie L Lindegaard, Walter Abhayaratna, Fozia Z Ahmed, Tuvia Ben-Gal, Vijay Chopra, Justin A Ezekowitz, Michael Fu, Hiroshi Ito, Małgorzata Lelonek, Vojtěch Melenovský, Bela Merkely, Julio Núñez, Eduardo Perna, Morten Schou, Michele Senni, Kavita Sharma, Peter van der Meer, Dirk Von Lewinski, Dennis Wolf, Sanjiv J Shah
BACKGROUND: Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target obesity-related heart failure with preserved ejection fraction in persons with type 2 diabetes. METHODS: We randomly assigned patients who had heart failure with preserved ejection fraction, a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or more, and type 2 diabetes to receive once-weekly semaglutide (2...
April 6, 2024: New England Journal of Medicine
#33
JOURNAL ARTICLE
Shingo Matsumoto, Mingming Yang, Li Shen, Alasdair Henderson, Brian L Claggett, Akshay S Desai, Martin Lefkowitz, Jean L Rouleau, Orly Vardeny, Michael R Zile, Pardeep S Jhund, Muthiah Vaduganathan, Scott D Solomon, John J V McMurray
AIMS: Patients with heart failure (HF) and preserved ejection fraction (HFpEF) have a particularly high prevalence of comorbidities, often necessitating treatment with many medications. The aim of this study was to evaluate the association between polypharmacy status and outcomes in PARAGON-HF. METHODS AND RESULTS: In this post hoc analysis, baseline medication status was available in 4793 of 4796 patients included in the primary analysis of PARAGON-HF. The effects of sacubitril/valsartan, compared with valsartan, were assessed according to the number of medications at baseline: 683 non-polypharmacy (<5 medications); 2750 polypharmacy (5-9 medications), and 1360 hyper-polypharmacy (≥10 medications)...
April 8, 2024: European Journal of Heart Failure
#34
JOURNAL ARTICLE
Hacer Basan, Emine Azak, İbrahim İlker Çetin, Esra Kiliç, Berrak Bilginer Gürbüz, Sümeyra Zeynep Özbey, Çiğdem Seher Kasapkara
INTRODUCTION: Primary carnitine deficiency (PCD) is a rare autosomal recessive disorder caused by loss of function mutations in the solute carrier family 22 member 5 ( SLC22A5 ) gene that encodes a high-affinity sodium-ion-dependent organic cation transporter protein (OCTN2). Carnitine deficiency can result in acute metabolic decompensation or, in a more insidious presentation, cardiomyopathy. Cardiomyopathy associated with PCD often presents with life-threatening heart failure. This presentation also usually includes skeletal muscle myopathy...
March 2024: Molecular Syndromology
#35
Santiago Luna-Alcala, Mauricio Garcia-Cardenas, Enrique C Guerra, Pavel Martinez-Dominguez, Aldo Cabello-Ganem, Leonardo Proaño-Bernal, Cristian A Chava-Ponte, Arturo Hernandez-Pacherres, Nilda Espinola-Zavaleta
Arrhythmogenic cardiomyopathy is a biventricular disease in which the effect on the left ventricle can be either equivalent to or more severe than that on the right ventricle. It is a rare disease due to its low reported prevalence and typically becomes clinically evident during the second to fourth decade of life. It represents 4% of sudden cardiac death cases referred for autopsy and 10% of cases of unexplained cardiac arrest. We present a challenging case report of a 68-year-old man who arrived at the emergency room with chest discomfort, palpitations, and light-headedness before a syncopal episode with urinary incontinence...
June 2024: Radiology Case Reports
#36
Truong Hoai Lam, Nguyen Thi Bach Yen, Nguyen Duc Hung, Nguyen Thu Trang, Tran Duc Minh, Nguyen Thi Duyen
Deep intertrabecular recesses and overly pronounced trabeculations in one ventricle are the hallmarks of noncompaction cardiomyopathy (NCCM), a rare congenital cardiomyopathy but very rarely right ventricle (RV), or both ventricles may be involved. We reported a 5-day-old preterm newborn with signs of congestive heart failure that the transthoracic echocardiography (TTE) revealed deep intertrabecular recesses perfused from the left ventricle (LV) and RV cavity, as well as significantly increased wall thickness of the right ventricles and hypertrabeculations in the apical and midventricular segments...
June 2024: Radiology Case Reports
#37
JOURNAL ARTICLE
Ayesha Abdul Qadir Memon, Areeba Shamim, Sanoober Mirza, Muhammad Osama, Iyad Naeem Muhammad, Calvin R Wei
Hypertrophic Cardiomyopathy (HCM) is a heart disease that can cause left ventricular hypertrophy, arrhythmias, heart failure, and sudden cardiac death. Currently, pharmacological treatment is limited and ineffective. Mavacamten (CamzyosTM) is a cardiac myosin inhibitor developed as a therapeutic option to reduce myocardial contractility and restoration of myocardial function. The Food and Drug Administration (FDA) approved the use of Mavacamten in 2022 for HCM symptoms. Clinical studies have proven that Mavacamten can reduce Left Ventricular Outflow Tract (LVOT) involvement, cardiac hypercontraction, and hypertrophy...
April 5, 2024: Cardiovascular & Hematological Agents in Medicinal Chemistry
#38
JOURNAL ARTICLE
Deanna L Palenzuela, Divyansh Agarwal, Karen Flanders, Erin Coglianese, Lana Tsao, David D'Alessandro, Gregory D Lewis, Michael Fitzsimons, Denise Gee
BACKGROUND: Obesity is an independent risk factor for heart failure (HF). Substantial weight loss has been shown to reverse obesity-related cardiomyopathy. This study aimed to report our institution's experience with laparoscopic sleeve gastrectomy (LSG) in patients with morbid obesity and end-stage HF. METHODS: Between 2018 and 2022, 26 patients with end-stage HF were referred for LSG. Of 26 patients, 16 underwent an operation, and 10 did not. After institutional review board approval, a retrospective electronic medical record review was performed to evaluate (i) age, (ii) preoperative weight, (iii) decrease in body mass index (BMI) score, (iv) whether the patient underwent heart transplantation, and (v) mortality...
April 2024: Journal of Gastrointestinal Surgery
#39
JOURNAL ARTICLE
Alexander T Sandhu, Jamie Calma, Megan Skye, Neil M Kalwani, Jimmy Zheng, Jessica Schirmer, Natasha Din, Cati Brown Johnson, Anshal Gupta, Roy Lan, Brian Yu, John A Spertus, Paul A Heidenreich
BACKGROUND: The impact of routine clinic use of patient-reported outcome (PRO) measures on clinical outcomes in patients with heart failure (HF) has not been well-characterized. We tested if clinic-based use of a disease-specific PRO improves patient-reported quality of life at 1 year. METHODS: PRO-HF was an open-label, parallel, patient-level randomized clinical trial of routine PRO assessment or usual care at an academic HF clinic between August 30, 2021, and June 30, 2022, with 1 year of follow-up...
April 7, 2024: Circulation
#40
JOURNAL ARTICLE
Rahul Dhawan, Mohamed Omer, Caitlin Carpenter, Paul A Friedman, Xiaoke Liu
BACKGROUND: Left bundle branch block (LBBB) induced cardiomyopathy is an increasingly recognized disease entity. However, no clinical testing has been shown to be able to predict such an occurrence. CASE REPORT: A 70-year-old male with a prior history of LBBB with preserved ejection fraction (EF) and no other known cardiovascular conditions presented with presyncope, high-grade AV block, and heart failure with reduced EF (36%). His coronary angiogram was negative for any obstructive disease...
April 7, 2024: Pacing and Clinical Electrophysiology: PACE
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
